Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Posts Q1 Revenue Increase, Narrowed Losses

NEW YORK, May 14 - DeCode Genetics reported an increase of first-quarter revenues today, amid narrowed net losses.


The Reykjavik, Icelandpopulation genomics company had revenues of $11.8 million for the first quarter, compared to $5.3 million for the same period last year.


The company's R&D expenses increased slightly to $19.8 million, compared to $18.8 million for the year-ago period. DeCode said this increase partly reflected the acquisition of its pharmaceuticals and biostructures groups.


In total, the company's net losses came to $13.0 million, compared to $15.9 million for the first quarter of 2002.


As of March 31, DeCode had $79.2 million in cash and cash equivalents.